The role of the bone microenvironment in skeletal metastasis

Journal of Bone Oncology

Volumn 2, Issue 1, 2013, Pages 47-57

  Zheng, Yu ^a,b   Zhou, Hong ^a   Dunstan, Colin R ^a   Sutherland, Robert L ^b   Seibel, Markus J ^a,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c Department of Microbiology and Infectious Diseases   (Australia)

Author keywords

Bone metastasis; Bone microenvironment; Bone remodelling; Cancer

Indexed keywords

ALENDRONIC ACID; CALCIUM; CLODRONIC ACID; DENOSUMAB; IBANDRONIC ACID; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPONTIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; VITAMIN D; VITRONECTIN; ZOLEDRONIC ACID;

BONE ATROPHY; BONE LESION; BONE MARROW; BONE MARROW CELL; BONE MATRIX; BONE METABOLISM; BONE METASTASIS; BONE REMODELING; BONE TURNOVER; BREAST CANCER; CALCIUM DEFICIENCY; CANCER CELL; CANCER PATIENT; CELL GROWTH; CELL SURVIVAL; HEMATOPOIETIC CELL; HUMAN; MESENCHYME CELL; MICROENVIRONMENT; MICROMETASTASIS; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST ACTIVITY; OSTEOCLASTOGENESIS; OSTEOCYTE; OSTEOLYSIS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

EID: 84882426625     PISSN: 22121374     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbo.2012.11.002     Document Type: Review

References (174)

1. Roodman GD. Mechanisms of bone metastasis. New England Journal of Medicine 2004;350: 1655-64.
2. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treatment Reviews 2001;27: 165-76. (Pubitemid 32452017)
3. Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. Natural Review of Cancer 2011;11: 411-25.
4. Lipton A, Berenson JR, Body JJ, Boyce BF, Bruland OS, Carducci MA, et al. Advances in treating metastatic bone cancer: summary statement for the First Cambridge Conference. Clinical Cancer Research 2006;12: 6209s-212ss.
5. Fukutomi M, Yokota M, Chuman H, Harada H, Zaitsu Y, Funakoshi A, et al. Increased incidence of bone metastases in hepatocellular carcinoma. European Journal of Gastroenterology and Hepatology 2001;13: 1083-8. (Pubitemid 32905203)
6. Husaini HA, Wheatley-Price P, Clemons M, Shepherd FA. Prevention and management of bone metastases in lung cancer a review. Journal of Thoracic Oncology 2009;4: 251-9.
7. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Natural Review of Cancer 2002;2: 584-93. (Pubitemid 37328925)
8. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Natural Review of Cancer 2003;3: 453-8. (Pubitemid 37328849)
9. Guise TA. The vicious cycle of bone metastases. Journal of Musculoskeletal Neuronal Interaction 2002;2: 570-2. (Pubitemid 36157607)
10. Yoneda T, Hiraga T. Crosstalk between cancer cells and bone microenviron-ment in bone metastasis. Biochemical and Biophysical Research Communications 2005;328: 679-87. (Pubitemid 40208305)
11. Mundy GR. Mechanisms of bone metastasis. Cancer 1997;80: 1546-56. (Pubitemid 27444026)
12. Guise TA, Mohammad KS, Clines G, Stebbins EG, Wong DH, Higgins LS, et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clinical Cancer Research 2006;12: 6213s-6s. (Pubitemid 44703792)
13. Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Research 2001;61: 4432-6. (Pubitemid 32685771)
14. Neudert M, Fischer C, Krempien B, Bauss F, Seibel MJ. Site-specific human breast cancer (MDA-MB-231) metastases in nude rats: model characterisation and in vivo effects of ibandronate on tumour growth. International Journal of Cancer 2003;107: 468-77. (Pubitemid 37266469)
15. Zheng Y, Zhou H, Brennan K, Blair JM, Modzelewski JR, Seibel MJ, et al. Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis. Bone 2007;40: 471-8. (Pubitemid 46070226)
16. Guise TA, Chirgwin JM. Role of bisphosphonates in prostate cancer bone metastases. Seminars in Oncology 2003;30: 717-23. (Pubitemid 37296796)
17. Hiraga T, Williams PJ, Mundy GR, Yoneda T. The bisphosphonate ibandro-nate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Research 2001;61: 4418-24. (Pubitemid 32685769)
18. Mundy GR, Yoneda T, Hiraga T. Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment. Seminars in Oncology 2001;28: 35-44. (Pubitemid 32494623)
19. Yoneda T, Sasaki A, Dunstan C, Williams PJ, Bauss F, De Clerck YA, et al. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. Journal of Clinical Investigation 1997;99: 2509-17. (Pubitemid 27227730)
20. Zhang J, Dai J, Qi Y, Lin DL, Smith P, Strayhorn C, et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. Journal of Clinical Investigation 2001;107: 1235-44. (Pubitemid 32494540)
21. Body JJ, Lipton A, Gralow J, Steger GG, Gao G, Yeh H, et al. Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure. Journal of Bone and Mineral Research 2009;25: 440-6.
22. Fizazi K, Bosserman L, Gao G, Skacel T, Markus R. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial. Journal of Urology 2009;182 509-15; discussion 15-6.
23. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. Journal of Clinical Oncology 2010;28: 5132-9.
24. Ooi LL, Zheng Y, Stalgis-Bilinski K, Dunstan CR. The bone remodeling environment is a factor in breast cancer bone metastasis. Bone 2011;48: 66-70.
25. Yonou H, Ochiai A, Ashimine S, Maeda H, Horiguchi Y, Yoshioka K, et al. The bisphosphonate YM529 inhibits osteoblastic bone tumor proliferation of prostate cancer. Prostate 2007;67: 999-1009. (Pubitemid 46828933)
26. Pecherstorfer M, Seibel MJ, Woitge HW, Horn E, Schuster J, Neuda J, et al. Bone resorption in multiple myeloma and in monoclonal gammopathy of undetermined significance: quantification by urinary pyridinium crosslinks of collagen. Blood 1997;90: 3743-50. (Pubitemid 27473447)
27. Diel IJ, Solomayer EF, Seibel MJ, Pfeilschifter J, Maisenbacher H, Gollan C, et al. Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis. Clinical Cancer Research 1999;5: 3914-9. (Pubitemid 30013765)
28. Woitge HW, Horn E, Keck AV, Auler B, Seibel MJ, Pecherstorfer M. Biochemical markers of bone formation in patients with plasma cell dyscrasias and benign osteoporosis. Clinical Chemistry 2001;47: 686-93. (Pubitemid 32275812)
29. Seibel MJ. Clinical use of markers of bone turnover in metastatic bone disease. Nat Clin Pract Oncol 2005;2: 504-17 quiz 1 p following 33. (Pubitemid 41553935)
30. Ali SM, Demers LM, Leitzel K, Harvey HA, Clemens D, Mallinak N, et al. Baseline serum NTx levels are prognostic in metastatic breast cancer patients with bone-only metastasis. Annals of Oncology 2004;15: 455-9. (Pubitemid 38444549)
31. Coleman RE, Major P, Lipton A, Brown JE, Lee KA, Smith M, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. Journal of Clinical Oncology 2005;23: 4925-35. (Pubitemid 46223998)
32. Cook RJ, Coleman R, Brown J, Lipton A, Major P, Hei YJ, et al. Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clinical Cancer Research 2006;12: 3361-7.
33. Lipton A, Costa L, Ali S, Demers L. Use of markers of bone turnover for monitoring bone metastases and the response to therapy. Seminars in Oncology 2001;28: 54-9. (Pubitemid 32844930)
34. Coleman RE, Guise TA, Lipton A, Roodman GD, Berenson JR, Body JJ, et al. Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference. Clinical Cancer Research 2008;14: 6387-95.
35. Lipton A. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 2008;113: 193-201. (Pubitemid 351976401)
36. Logothetis CJ, Lin SH. Osteoblasts in prostate cancer metastasis to bone. Natural Review of Cancer 2005;5: 21-8. (Pubitemid 40052322)
37. Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. Journal of the National Cancer Institute 2005;97: 59-69.
38. Costa L, Demers LM, Gouveia-Oliveira A, Schaller J, Costa EB, de Moura MC, et al. Prospective evaluation of the peptide-bound collagen type I crosslinks N-telopeptide and C-telopeptide in predicting bone metastases status. Journal of Clinical Oncology 2002;20: 850-6. (Pubitemid 34111395)
39. Siclari VA, Guise TA, Chirgwin JM. Molecular interactions between breast cancer cells and the bone microenvironment drive skeletal metastases. Cancer and Metastasis Reviews 2006;25: 621-33. (Pubitemid 46075000)
40. Aft R. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncology 2010;11: 421-8.
41. Hauschka PV, Mavrakos AE, Iafrati MD, Doleman SE, Klagsbrun M. Growth factors in bone matrix. Isolation of multiple types by affinity chromato-graphy on heparin-Sepharose. Journal of Biological Chemistry 1986;261: 12665-74. (Pubitemid 17204223)
42. Aubin JE. Advances in the osteoblast lineage. Biochemistry and Cell Biology 1998;76: 899-910. (Pubitemid 29450559)
43. Mundy GR, Chen D, Zhao M, Dallas S, Xu C, Harris S. Growth regulatory factors and bone. Reviews in Endocrinology & Metabolism Disorders 2001;2: 105-15. (Pubitemid 33643897)
44. Vessella RL, Corey E. Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis. Clinical Cancer Research 2006;12: 6285s-290ss.
45. Kingsley LA, Fournier PG, Chirgwin JM, Guise TA. Molecular biology of bone metastasis. Molecular Cancer Therapy 2007;6: 2609-17. (Pubitemid 350058141)
46. Lemaire V, FLFL Tobin, Greller LD, Cho CR, Suva LJ. Modeling the interactions between osteoblast and osteoclast activities in bone remodeling. Journal of Theoretical Biology 2004;229: 293-309. (Pubitemid 38844935)
47. Frost HM. Metabolism of bone. New England Journal of Medicine 1973;289: 864-5.
48. Parfitt AM. The mechanism of coupling: a role for the vasculature. Bone 2000;26: 319-23.
49. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423: 337-42. (Pubitemid 40852708)
50. Aarden EM, Burger EH, Nijweide PJ. Function of osteocytes in bone. Journal of Cellular Biochemistry 1994;55: 287-99. (Pubitemid 24218803)
51. Smith R. Physiology of bone. Oxford Textbook of Medicine. 2002: p.3.133.
52. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997;390: 175-9. (Pubitemid 27507987)
53. Wong BR, Rho J, Arron J, Robinson E, Orlinick J, Chao M, et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. Journal of Biological Chemistry 1997;272: 25190-4. (Pubitemid 27415705)
54. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proceedings of the National Academy of Sciences of the United States of America 1998;95: 3597-602.
55. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93: 165-76. (Pubitemid 28180851)
56. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397: 315-23.
57. Li J, Sarosi I, Yan XQ, Morony S, Capparelli C, Tan HL, et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogen-esis and regulation of bone mass and calcium metabolism. Proceedings of the National Academy of Sciences of the United States of America 2000;97: 1566-71. (Pubitemid 30118482)
58. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89: 309-19. (Pubitemid 27199902)
59. Morony S, Capparelli C, Lee R, Shimamoto G, Boone T, Lacey DL, et al. A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1beta, TNF-alpha, PTH, PTHrP, and 1, 25(OH)2D3. Journal of Bone and Mineral Research 1999;14: 1478-85. (Pubitemid 29416673)
60. Ooi LL, Zhou H, Kalak R, Zheng Y, Conigrave AD, Seibel MJ, et al. Vitamin D deficiency promotes human breast cancer growth in a murine model of bone metastasis. Cancer Research 2010;70: 1835-44.
61. Quinn JE, Brown LG, Zhang J, Keller ET, Vessella RL, Corey E. Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms. Prostate Cancer Prostatic Disease 2005;8: 253-9. (Pubitemid 43118063)
62. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. Journal of Bone and Mineral Research 2000;15: 2-12. (Pubitemid 30026926)
63. Theill LE, Boyle WJ, Penninger JM. RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annual Review of Immunology 2002;20: 795-823. (Pubitemid 34293440)
64. Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR. The effect of a single dose of osteoprotegerin in postmenopausal women. Journal of Bone and Mineral Research 2001;16: 348-60. (Pubitemid 32105416)
65. Bekker PJ, Holloway DL, Rasmussen AS, Murphy R, Martin SW, Leese PT, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. Journal of Bone and Mineral Research 2004;19: 1059-66. (Pubitemid 41110556)
66. Mundy GR, Guise TA. Hypercalcemia of malignancy. American Journal of Medicine 1997;103: 134-45. (Pubitemid 27352118)
67. Boucharaba A, Serre CM, Gres S, Saulnier-Blache JS, Bordet JC, Guglielmi J, et al. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. Journal of Clinical Investigation 2004;114: 1714-25. (Pubitemid 40385527)
68. Knupfer H, Preiss R. Significance of interleukin-6 (IL-6) in breast cancer (review). Breast Cancer Research and Treatment 2007;102: 129-35. (Pubitemid 46452175)
69. Burtis WJ, Brady TG, Orloff JJ, Ersbak JB, Warrell Jr RP, Olson BR, et al. Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer. New England Journal of Medicine 1990;322: 1106-12. (Pubitemid 20149527)
70. Kakonen SM, Selander KS, Chirgwin JM, Yin JJ, Burns S, Rankin WA, et al. Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. Journal of Biological Chemistry 2002;277: 24571-8. (Pubitemid 34951984)
71. Li J, Karaplis AC, Huang DC, Siegel PM, Camirand A, Yang XF, et al. PTHrP drives breast tumor initiation, progression, and metastasis in mice and is a potential therapy target. Journal of Clinical Investigation 2011;121: 4655-69.
72. Moseley JM, Kubota M, Diefenbach-Jagger H, Wettenhall RE, Kemp BE, Suva LJ, et al. Parathyroid hormone-related protein purified from a human lung cancer cell line. Proceedings of the National Academy of Sciences of the United States of America 1987;84: 5048-52. (Pubitemid 17095861)
73. Suva LJ, Winslow GA, Wettenhall RE, Hammonds RG, Moseley JM, Diefenbach-Jagger H, et al. A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression. Science 1987;237: 893-6. (Pubitemid 17128278)
74. Strewler GJ, Stern PH, Jacobs JW, Eveloff J, Klein RF, Leung SC, et al. Parathyroid hormonelike protein from human renal carcinoma cells. Structural and functional homology with parathyroid hormone. Journal of Clinical Investigation 1987;80 1803-1807. (Pubitemid 18007159)
75. Kemp BE, Moseley JM, Rodda CP, Ebeling PR, Wettenhall RE, Stapleton D, et al. Parathyroid hormone-related protein of malignancy: active synthetic fragments. Science 1987;238: 1568-70. (Pubitemid 18032472)
76. Abou-Samra AB, Juppner H, Force T, Freeman MW, Kong XF, Schipani E, et al. Expression cloning of a common receptor for parathyroid hormone and parathyroid hormone-related peptide from rat osteoblast-like cells: a single receptor stimulates intracellular accumulation of both cAMP and inositol trisphosphates and increases intracellular free calcium. Proceedings of the National Academy of Sciences of the United States of America 1992;89: 2732-6.
77. Horiuchi N, Caulfield MP, Fisher JE, Goldman ME, McKee RL, Reagan JE, et al. Similarity of synthetic peptide from human tumor to parathyroid hormone in vivo and in vitro. Science 1987;238: 1566-8. (Pubitemid 18032471)
78. Guise TA. Parathyroid hormone-related protein and bone metastases. Cancer 1997;80: 1572-80. (Pubitemid 27444029)
79. Capparelli C, Kostenuik PJ, Morony S, Starnes C, Weimann B, Van G, et al. Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. Cancer Research 2000;60: 783-7. (Pubitemid 30129501)
80. Morony S, Warmington K, Adamu S, Asuncion F, Geng Z, Grisanti M, et al. The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy. Endocrinology 2005;146: 3235-43. (Pubitemid 41058092)
81. Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Wieser R, et al. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. Journal of Clinical Investigation 1999;103: 197-206. (Pubitemid 29053137)
82. Thomas RJ, Guise TA, Yin JJ, Elliott J, Horwood NJ, Martin TJ, et al. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 1999;140: 4451-8. (Pubitemid 30666108)
83. Henderson M, Danks J, Moseley J, Slavin J, Harris T, McKinlay M, et al. Parathyroid hormone-related protein production by breast cancers, improved survival, and reduced bone metastases. Journal of the National Cancer Institute 2001;93: 234-7. (Pubitemid 32166495)
84. Guise TA, O'Keefe R, Randall RL, Terek RM. Molecular biology and therapeutics in musculoskeletal oncology. Journal of Bone and Joint Surgery. American Volume 2009;91: 724-32.
85. Bendre MS, Margulies AG, Walser B, Akel NS, Bhattacharrya S, Skinner RA, et al. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway. Cancer Research 2005;65: 11001-9. (Pubitemid 41713370)
86. Bendre MS, Montague DC, Peery T, Akel NS, Gaddy D, Suva LJ. Interleukin-8 stimulation of steoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. Bone 2003;33: 28-37. (Pubitemid 36952685)
87. Clines GA, Guise TA. Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone. Endocrine-Related Cancer 2005;12: 549-83. (Pubitemid 41482993)
88. Hu Z, Gupta J, Zhang Z, Gerseny H, Berg A, Chen YJ, et al. Systemic delivery of oncolytic adenoviruses targeting transforming growth factor-beta inhibits established bone metastasis in a prostate cancer mouse model. Human Gene Therapy 2012;23: 871-82.
89. Javelaud D, Alexaki VI, Dennler S, Mohammad KS, Guise TA, Mauviel A. TGF-beta/SMAD/GLI2 signaling axis in cancer progression and metastasis. Cancer Research 2011;71: 5606-10.
90. Mohammad KS, Javelaud D, Fournier PG, Niewolna M, McKenna CR, Peng XH, et al. TGF-beta-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases. Cancer Research 2011;71: 175-84.
91. Juarez P, Guise TA. TGF-beta in cancer and bone: implications for treatment of bone metastases. Bone 2011;48: 23-9.
92. Hiraga T, Myoui A, Hashimoto N, Sasaki A, Hata K, Morita Y, et al. Bone-derived IGF mediates crosstalk between bone and breast cancer cells in bony metastases. Cancer Research 2012;72: 4238-49.
93. Kim SJ, Uehara H, Yazici S, Langley RR, He J, Tsan R, et al. Simultaneous blockade of platelet-derived growth factor-receptor and epidermal growth factor-receptor signaling and systemic administration of paclitaxel as therapy for human prostate cancer metastasis in bone of nude mice. Cancer Research 2004;64: 4201-8. (Pubitemid 38802424)
94. Russell MR, Jamieson WL, Dolloff NG, Fatatis A. The alpha-receptor for platelet-derived growth factor as a target for antibody-mediated inhibition of skeletal metastases from prostate cancer cells. Oncogene 2009;28: 412-21.
95. Uehara H, Kim SJ, Karashima T, Shepherd DL, Fan D, Tsan R, et al. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. Journal of the National Cancer Institute 2003;95: 458-70. (Pubitemid 36432420)
96. Sethi N, Kang Y. Dysregulation of developmental pathways in bone metastasis. Bone 2011;48: 16-22.
97. Clezardin P, Ebetino FH, Fournier PG. Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Cancer Research 2005;65: 4971-4. (Pubitemid 40827299)
98. Holen I, Shipman CM. Role of osteoprotegerin (OPG) in cancer. Clinical Science (London) 2006;110: 279-91. (Pubitemid 43348393)
99. Coleman RE, Lipton A, Roodman GD, Guise TA, Boyce BF, Brufsky AM, et al. Metastasis and bone loss: advancing treatment and prevention. Cancer Treatment Reviews 2010;36: 615-20.
100. Jin JK, Dayyani F, Gallick GE. Steps in prostate cancer progression that lead to bone metastasis. International Journal of Cancer 2011;128: 2545-61.
101. Patel LR, Camacho DF, Shiozawa Y, Pienta KJ, Taichman RS. Mechanisms of cancer cell metastasis to the bone: a multistep process. Future Oncology 2011;7: 1285-97.
102. Sturge J, Caley MP, Waxman J. Bone metastasis in prostate cancer: emerging therapeutic strategies. Natural Review of Clinical Oncology 2011;8: 357-68.
103. Russell RG, Smith R, Preston C, Walton RJ, Woods CG. Diphosphonates in Paget's disease. Lancet 1974;1: 894-8.
104. Russell RG. Bisphosphonates: the first 40 years. Bone 2011;49: 2-19.
105. Fleisch H, Russell RG, Francis MD. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 1969;165: 1262-4.
106. Padalecki SS, Guise TA. Actions of bisphosphonates in animal models of breast cancer. Breast Cancer Research 2002;4: 35-41. (Pubitemid 34097555)
107. Epstein S, Zaidi M. Biological properties and mechanism of action of ibandronate: application to the treatment of osteoporosis. Bone 2005;37: 433-40. (Pubitemid 41317315)
108. Fromigué O, Lagneaux L, Body JJ. Bisphosphonates induce breast cancer cell death in vitro. Journal of Bone and Mineral Research 2000;15: 2211-21.
109. Bauss F, Body JJ. Ibandronate in metastatic bone disease: a review of preclinical data. Anticancer Drugs 2005;16: 107-18. (Pubitemid 40250605)
110. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. Journal of Clinical Investigation 1991;88: 2095-105.
111. Gainford MC, Dranitsaris G, Clemons M. Recent developments in bispho-sphonates for patients with metastatic breast cancer. BMJ 2005;330: 769-73. (Pubitemid 40522339)
112. Coleman RE. The role of bisphosphonates in breast cancer. Breast 2004;13(Suppl 1): S19-28. (Pubitemid 39654740)
113. Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, et al. American Society of Clinical Oncology 2003 Update on the role of bispho-sphonates and bone health issues in women with breast cancer 10.1200/JCO.2003.08.017. Journal of Clinical Oncology 2003;21: 4042-4057. (Pubitemid 46606220)
114. Paterson AH. The role of bisphosphonates in early breast cancer. Oncologist 2006;11(Suppl 1): 13-9.
115. Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. New England Journal of Medicine 1998;339: 357-63. (Pubitemid 28363797)
116. Mason MD, Sydes MR, Glaholm J, Langley RE, Huddart RA, Sokal M, et al. Oral sodium clodronate for nonmetastatic prostate cancer-results of a randomized double-blind placebo-controlled trial: medical research council PR04 (ISRCTN61384873). Journal of the National Cancer Institute 2007;99: 765-76. (Pubitemid 47073523)
117. Powles T, Paterson S, Kanis JA, McCloskey E, Ashley S, Tidy A, et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. Journal of Clinical Oncology 2002;20: 3219-24. (Pubitemid 34831518)
118. Saarto T, Vehmanen L, Virkkunen P, Blomqvist C. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncologica 2004;43: 650-6. (Pubitemid 39563937)
119. Powles T, Paterson A, McCloskey E, Schein P, Scheffler B, Tidy A, et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Research 2006;8: R13.
120. Saarto T, Blomqvist C, Virkkunen P, Elomaa I. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. Journal of Clinical Oncology 2001;19: 10-7. (Pubitemid 32063474)
121. Body JJ. Bisphosphonates in the treatment of metastatic breast cancer. Journal of Mammary Gland Biology and Neoplasia 2001;6: 477-85.
122. Conte PF, Latreille J, Mauriac L, Calabresi F, Santos R, Campos D, et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. Journal of Clinical Oncology 1996;14: 2552-9. (Pubitemid 26300123)
123. Aft R, Naughton M, Trinkaus K, Watson M, Ylagan L, Chavez-MacGregor M, et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncology 2010;11: 421-8.
124. Weinfurt KP, Anstrom KJ, Castel LD, Schulman KA, Saad F. Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer. Annals of Oncology 2006;17: 986-9. (Pubitemid 43778991)
125. Li EC, Davis LE. Zoledronic acid: a new parenteral bisphosphonate. Clinical Therapeutics 2003;25: 2669-708. (Pubitemid 37510584)
126. Hadji P, Coleman R, Gnant M, Green J. The impact of menopause on bone, zoledronic acid, and implications for breast cancer growth and metastasis. Annals of Oncology 2012;23: 2782-90.
127. Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Heck D, Menzel C, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncology 2011;12: 631-41.
128. Pfeiler G, Konigsberg R, Fesl C, Mlineritsch B, Stoeger H, Singer CF, et al. Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. Journal of Clinical Oncology 2011;29: 2653-9.
129. Coleman R, Woodward E, Brown J, Cameron D, Bell R, Dodwell D, et al. Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer. Breast Cancer Research and Treatment 2011;127: 429-38.
130. Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, et al. Breast-cancer adjuvant therapy with zoledronic acid. New England Journal of Medicine 2011;365: 1396-405.
131. Gnant M. Intravenous bisphosphonates for breast cancer: impact on patient outcomes and scientific concepts. Breast Disease 2011;33: 71-81.
132. Bundred NJ, Campbell ID, Davidson N, DeBoer RH, Eidtmann H, Monnier A, et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. Cancer 2008;112: 1001-10. (Pubitemid 351304583)
133. Eidtmann H, de Boer R, Bundred N, Llombart-Cussac A, Davidson N, Neven P, et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Annals of Oncology 2010;21: 2188-94.
134. Llombart A, Frassoldati A, Paija O, Sleeboom HP, Jerusalem G, Mebis J, et al. Immediate administration of zoledronic acid reduces aromatase inhibitor-aAssociated bone loss in postmenopausal women with early breast cancer: 12-month analysis of the E-ZO-FAST trial. Clinical Breast Cancer 2012;12: 40-8.
135. Barrett J, Worth E, Bauss F, Epstein S. Ibandronate: a clinical pharmacological and pharmacokinetic update. Journal of Clinical Pharmacology 2004;44: 951-65. (Pubitemid 39096810)
136. Russell RG. Ibandronate: pharmacology and preclinical studies. Bone 2006;38 S7-12.
137. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Postlberger S, Menzel C, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. New England Journal of Medicine 2009;360: 679-91.
138. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, et al. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes and Development 1998;12: 1260-8. (Pubitemid 28213402)
139. Lacey DL, Tan HL, Lu J, Kaufman S, Van G, Qiu W, et al. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. American Journal of Pathology 2000;157: 435-48. (Pubitemid 30626907)
140. Body JJ, Greipp P, Coleman RE, Facon T, Geurs F, Fermand JP, et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 2003;97: 887-92. (Pubitemid 36125828)
141. Body JJ, Facon T, Coleman RE, Lipton A, Geurs F, Fan M, et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clinical Cancer Research 2006;12: 1221-8. (Pubitemid 43342512)
142. Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 2012;379: 39-46.
143. Gonzalez-Suarez E, Jacob AP, Jones J, Miller R, Roudier-Meyer MP, Erwert R, et al. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature. 2010;Epub ahead of print.
144. Goblirsch MJ, Zwolak PP, Clohisy DR, Roodman, Guise, Coleman, et al. Biology of bone cancer pain. Clinical Cancer Research 2006;12: 6231s-35ss.
145. Honore P, Luger NM, Sabino MAC, Schwei MJ, Rogers SD, Mach DB, et al. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nature Medicine 2000;6: 521-8. (Pubitemid 30305901)
146. Libouban H, Moreau MF, Basle MF, Bataille R, Chappard D. Increased bone remodeling due to ovariectomy dramatically increases tumoral growth in the 5T2 multiple myeloma mouse model. Bone 2003;33: 283-92. (Pubitemid 37103245)
147. Hirbe AC, Uluckan O, Morgan EA, Eagleton MC, Prior JL, Piwnica-Worms D, et al. Granulocyte colony-stimulating factor enhances bone tumor growth in mice in an osteoclast-dependent manner. Blood 2007;109: 3424-31. (Pubitemid 46572532)
148. Price JT, Quinn JM, Sims NA, Vieusseux J, Waldeck K, Docherty SE, et al. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamy-cin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line. Cancer Research 2005;65: 4929-38. (Pubitemid 40740833)
149. Woitge HW, Pecherstorfer M, Horn E, Keck AV, Diel IJ, Bayer P, et al. Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma. British Journal of Cancer 2001;84: 344-51. (Pubitemid 32154427)
150. Brown JE, Thomson CS, Ellis SP, Gutcher SA, Purohit OP, Coleman RE. Bone resorption predicts for skeletal complications in metastatic bone disease. British Journal of Cancer 2003;89: 2031-7. (Pubitemid 38030899)
151. Blair JM, Zhou H, Seibel MJ, Dunstan CR. Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis. Natural Clinical Practice Oncology 2006;3: 41-9. (Pubitemid 43108833)
152. Fohr B, Dunstan CR, Seibel MJ. Clinical review 165: markers of bone remodeling in metastatic bone disease. Journal of Clinical Endocrinology and Metabolism 2003;88: 5059-75. (Pubitemid 37452696)
153. Seibel M. Bone remodelling markers and bone cancer. In: Heyman E, editor. Recent advances in bone cancer: progression and therapeutic approaches. Elsevier; 2011. p. 253-64.
154. Seibel MJ. The use of molecular markers of bone turnover in the management of patients with metastatic bone disease. Clin ical Endocrinology (Oxford) 2008;68: 839-49. (Pubitemid 351703933)
155. Lagunova Z, Porojnicu AC, Dahlback A, Berg JP, Beer TM, Moan J. Prostate cancer survival is dependent on season of diagnosis. Prostate 2007;67: 1362-70. (Pubitemid 47435784)
156. Li H, Stampfer MJ, Hollis JB, Mucci LA, Gaziano JM, Hunter D, et al. A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Medicine 2007;4: e103.
157. Grant WB. Geographic variation of prostate cancer mortality rates in the United States: implications for prostate cancer risk related to vitamin D. International Journal of Cancer 2004;111: 470-1 author reply 2.
158. Zheng Y, Zhou H, Modzelewski JR, Kalak R, Blair JM, Seibel MJ, et al. Accelerated bone resorption, due to dietary calcium deficiency, promotes breast cancer tumor growth in bone. Cancer Research 2007;67: 9542-8. (Pubitemid 47535945)
159. Zheng Y, Zhou H, Fong-Yee C, Modzelewski JR, Seibel MJ, Dunstan CR. Bone resorption increases tumour growth in a mouse model of osteosclerotic breast cancer metastasis. Clinical and Experimental Metastasis 2008;25: 559-67.
160. Ooi LL, Zheng Y, Zhou H, TrivediT, Conigrave AD, Seibel MJ, et al. Vitamin D deficiency promotes growth of MCF-7 human breast cancer in a rodent model of osteosclerotic bone metastasis. Bone 2010;47: 795-803.
161. Zheng Y, Zhou H, Ooi LL, Snir AD, Dunstan CR, Seibel MJ. Vitamin D deficiency promotes prostate cancer growth in bone. Prostate 2011;15: 1012-21.
162. Park SI, Soki FN, McCauley LK. Roles of bone marrow cells in skeletal metastases: no longer bystanders. Cancer Microenviron 2011;4: 237-46.
163. Takayanagi H. Osteoimmunology and the effects of the immune system on bone. Nature Reviews Rheumatology 2009;5: 667-76.
164. Sato K. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. Journal of Experimetnal Medicine 2006;203: 2673-82. (Pubitemid 44833343)
165. Kaplan RN, Psaila B, Lyden D. Bone marrow cells in the 'pre-metastatic niche': within bone and beyond. Cancer and Metastasis Reviews 2006;25: 521-9. (Pubitemid 46071861)
166. Kaplan RN. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005;438: 820-7. (Pubitemid 41753060)
167. Hiratsuka S, Watanabe A, Sakurai Y, Akashi-Takamura S, Ishibashi S, Miyake K, et al. The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Natural Cell Biol 2008;10: 1349-55.
168. Huang Y, Song N, Ding Y, Yuan S, Li X, Cai H, et al. Pulmonary vascular destabilization in the premetastatic phase facilitates lung metastasis. Cancer Research 2009;69: 7529-37.
169. Sun YX, Schneider A, Jung Y, Wang J, Dai J, CookK, et al. Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. Journal of Bone and Mineral Research 2005;20: 318-29.
170. Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, Boyce BF, et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. Journal of Clinical Investigation 1996;98: 1544-9. (Pubitemid 26327863)
171. Kelly T. Expression of heparanase by primary breast tumors promotes bone resorption in the absence of detectable bone metastases. Cancer Research 2005;65: 5778-84. (Pubitemid 40911181)
172. Pazolli E. Senescent stromal-derived osteopontin promotes preneoplastic cell growth. Cancer Research 2009;69: 1230-9.
173. McAllister SS. Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell 2008;133: 994-1005. (Pubitemid 351787747)
174. Lynch CC. MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell 2005;7: 485-96. (Pubitemid 40719131)